[A15-48] Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Last updated 01.03.2016
Project no.:
A15-48
Commission:
Commission awarded on 23.11.2015 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-87 | Fingolimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-19 | Fingolimod (new therapeutic indication) - Addendum to Commission A15-48 | Commission completed |
| A15-12 | Fingolimod - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A11-23 | Fingolimod - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A14-21 | Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2016-05-19 A G-BA decision was published.